Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02(D) Malaria Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial

BACKGROUND: The RTS,S/AS02(D) vaccine has been shown to have a promising safety profile, to be immunogenic and to confer protection against malaria in children and infants. METHODS AND FINDINGS: We did a randomized, controlled, phase I/IIb trial of RTS,S/AS02(D) given at 10, 14 and 18 weeks of age s...

Descripción completa

Detalles Bibliográficos
Autores principales: Aide, Pedro, Aponte, John J., Renom, Montse, Nhampossa, Tacilta, Sacarlal, Jahit, Mandomando, Inacio, Bassat, Quique, Manaca, Maria Nélia, Leach, Amanda, Lievens, Marc, Vekemans, Johan, Dubois, Marie-Claude, Loucq, Christian, Ballou, W. Ripley, Cohen, Joe, Alonso, Pedro L.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2973956/
https://www.ncbi.nlm.nih.gov/pubmed/21079803
http://dx.doi.org/10.1371/journal.pone.0013838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2973956/
https://www.ncbi.nlm.nih.gov/pubmed/21079803
http://dx.doi.org/10.1371/journal.pone.0013838

Ejemplares similares